This page is updated frequently with information related to COVID-19 and sponsored programs research. We will continue to add links and list resources as new information becomes available.
Hanover Research is closely monitoring developments surrounding the Coronavirus Disease 2019 (COVID-19) and how it has and may continue to impact the higher education and health research communities. For information, visit the web page Grant Alerts: COVID-19 & Health Research. If you have any questions, contact your grants manager or Charlotte Johnson, Director of Office of Sponsored Programs at email@example.com.
NIH has published several notices regarding the funding status of current and future grants and contracts in the wake of COVID-19. The Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients page was published by NIH on 3/16/20 and includes all previous NIH communications regarding the coronavirus. It will be updated regularly. Below are the notices most relevant to DPM. If you have any questions, contact your grants manager or Charlotte Johnson, Director of Office of Sponsored Programs at firstname.lastname@example.org.
NOT-OD-20-091-UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)
NOT-OD-20-086 – Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19
NOT-OD-20-087- Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
NOT-OD-20-083 - General Frequently Asked Questions (FAQs)Proposal Submission and Award Management Related to COVID-19
This video provides an update for applicants and recipients of federal funding on flexibilities NIH has put in place to support them and their research through the disruptions caused by COVID-19.
Of other interest:
NOT-CA-20-033 -Notice on Policy Regarding Minimum Level of Effort for NCI-Funded Awards
In response to questions from the research community, the Office for Human Research Protections (OHRP) is offering guidance on how the HHS human subjects protection regulations (45 CFR part 46) apply to actions taken by institutions and investigators in response to the COVID-19 outbreak. If you have any questions, contact Paula Tebeau, Senior Compliance Manager, IRB at email@example.com.
U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration (FDA) plays a critical role in protecting the United States from threats including emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. If you have any questions, contact Paula Tebeau, Senior Compliance Manager, IRB at firstname.lastname@example.org.
The following alert from Verrill Dana provides an easy-to-read list of potential COVID-19 issues on human subjects research. For questions specific to IRB review, please contact Paula Tebeau, Senior Compliance Manager, IRB at email@example.com.